PHV-wordings
Here you will find safety-relevant information that must be implemented in the corresponding product information due to a PHV (pharmacovigilance) issues.
Due to the relaunch of the EMA website in December 2023, you will find the current links to the entries prior to December 01, 2023 at https://www.ema.europa.eu
Amplodipine/Atorvastatin
PSUR-outcome
|
15/12/2025
Further information and amendments to the product information in all EU languages are available on the EMA website.
Trimethoprim (Mono)
Additional template
|
04/12/2025
Further information regarding SmPC harmonisation are available in Coordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh) Minutes for the meeting on 14-15 October 2025.
Propylthiouracil
PSUR-outcome
|
03/12/2025
Further information and amendments to the product information in all EU languages are available on the EMA website.
Vancomycin
PSUR-outcome
|
02/12/2025
Further information and amendments to the product information in all EU languages are available on the EMA website.
Codeine
PSUR-outcome
|
28/11/2025
Further information and amendments to the product information in all EU languages are available on the EMA website.
Atenolol
PSUR-outcome
|
28/11/2025
Further information and amendments to the product information in all EU languages are available on the EMA website.
Dorzolamide/Timolol
Additional template
|
27/11/2025
Further information can be found in the CMDh minutes from october 2025.
Dorzolamide
PSUR-outcome
|
27/11/2025
Further information and amendments to the product information in all EU languages are available on the EMA website.
Gabapentin
PSUR-outcome
|
27/11/2025
Further information and amendments to the product information in all EU languages are available on the EMA website.
Prednisone
PSUR-outcome
|
26/11/2025
Further information and amendments to the product information in all EU languages are available on the EMA website.
